

Amendment to the Claims



This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-129 (canceled)

Claim 130 (Previously Presented): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an anti-virally effective amount of a β -D-2'-methyl-ribofuranosyl nucleoside or a pharmaceutically acceptable salt or ester thereof.

Claim 131 (Previously Presented): The method of claim 130, wherein the nucleoside is a pyrimidine nucleoside.

Claim 132 (Previously Presented): The method of claim 130, wherein the nucleoside is a purine nucleoside.

Claim 133 (Previously Presented) The method of claim 130 wherein the β -D-2'-methyl-ribofuranosyl nucleoside is administered in combination or alternation with a second anti-flavivirus or anti-pestivirus agent.

Claim 134 (Previously Presented): The method of claim 133, wherein the second anti-flavivirus or anti-pestivirus agent is selected from the group consisting of interferon, ribavirin, a protease inhibitor, a thiazolidine derivative, a polymerase inhibitor, and a helicase inhibitor.

Claim 135 (Previously Presented): The method of claim 134, wherein the second anti-flavivirus or anti-pestivirus agent is interferon.

Application No. 10/602,694
Amendment dated August 24, 2005
Responsive to Office Action dated April 6, 2005

Claim 136 (Previously Presented): The method of claim 134, wherein the second anti-flavivirus or anti-pestivirus agent is ribavirin.

Claim 137 (Previously Presented): The method of claim 130, wherein the compound is in the form of a dosage unit.

Claim 138 (Previously Presented): The method of claim 137, wherein the dosage unit contains 50 to 1000 mg of the β -D-2'-methyl-ribofuranosyl nucleoside.

Claim 139 (Previously Presented): The method of claim 137, wherein said dosage unit is a tablet or capsule.

Claim 140 (Previously Presented): The method of claim 130, wherein the host is a human.

Claim 141 (Previously Presented): The method of claim 130, wherein the β -D-2'-methyl-ribofuranosyl nucleoside is in substantially pure form.

Claim 142 (Previously Presented): The method of claim 141, wherein the β -D-2'-methyl-ribofuranosyl nucleoside is at least 90% by weight of the β -D-isomer.

Claim 143 (Previously Presented): The method of claim 141, wherein the β -D-2'-methyl-ribofuranosyl nucleoside is at least 95% by weight of the β -D-isomer.

Claim 144 (Previously Presented): The method of claim 130, wherein the flavivirus or pestivirus is a Dengue virus.

Claim 145 (Previously Presented): The method of claim 130, wherein the flavivirus or pestivirus is a West Nile virus.

Claim 146 (Previously Presented): The method of claim 130, wherein the flavivirus or pestivirus is a yellow fever virus.

Claim 147 (Previously Presented): The method of claim 130, wherein the flavivirus or pestivirus is a bovine viral diarrhea virus (BVDV).

Claim 148 (Canceled)

Claim 149 (New): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an anti-virally effective amount of a β -D-2'-methyl-furanosyl nucleoside or a pharmaceutically acceptable salt or ester thereof.

Claim 150 (New): The method of claim 149, wherein the nucleoside is a pyrimidine nucleoside.

Claim 151 (New): The method of claim 149, wherein the nucleoside is a purine nucleoside.

Claim 152 (New): The method of claim 149, wherein the host is a human.

Claim 153 (New): The method of claim 149, wherein the β -D-2'-methyl-furanosyl nucleoside is in substantially pure form.